The clinical presentation of Parkinson's disease (PD) is both complex and heterogeneous,
and its precise classification often requires an intensive work-up. The differential diagnosis …

The colony-stimulating factor 1 receptor (CSF1R) is a key tyrosine kinase transmembrane
receptor modulating microglial homeostasis, neurogenesis, and neuronal survival in the …

Background Blood-based test for predicting disease progression and early diagnosis of
Parkinson's disease (PD) is an unmet need in the clinic. The profiles of microRNAs …

The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …

One of the most pressing challenges in the clinical research of neurodegenerative diseases
(NDDs) is the validation and standardization of pathophysiological biomarkers for different …

Movement disorders have been carefully clinically defined, based on clinico‐pathological
series; however there is often diagnostic and prognostic uncertainty, especially in early …

Background Parkinson's disease (PD) is associated with cognitive decline through multiple
mechanisms, including Alzheimer's disease (AD) pathology and cortical Lewy body …

Background Neurofilament light in serum (sNfL) is a biomarker for axonal damage with
elevated levels in many neurological disorders, including neurodegenerative dementias …

Parkinson's disease (PD) is a heterogeneous movement disorder with different motor
subtypes including tremor dominant (TD), indeterminate and postural instability, and gait …

Background: Neurofilament light (NfL) can reflect the extent of neuron/axon damage, thus
providing an opportunity to examine the severity and progression of the diseases with such …